Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
02 December 2022 - 07:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION
OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File
No. 001-36152
Aerie
Pharmaceuticals, Inc.
(Exact name of
registrant as specified in its charter)
4301
Emperor Blvd., Suite 400
Durham,
North Carolina 27703
(919) 237-5300
(Address,
including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
Common Stock,
par value $0.001 per share
(Title of each
class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under
Section 13(a) or 15(d) remains)
Please place an X in the box(es) to
designate the appropriate rule provision(s) relied upon to
terminate or suspend the duty to file reports:
| |
Rule 12g-4(a)(1)
|
☒ |
|
|
|
Rule 12g-4(a)(2)
|
☐ |
|
|
|
Rule 12h-3(b)(1)(i)
|
☒ |
|
|
|
Rule 12h-3(b)(1)(ii)
|
☐ |
|
|
|
Rule 15d-6
|
☐ |
|
|
|
Rule 15d-22(b)
|
☐ |
|
Approximate number of holders of
record as of the certification or notice date: 1
Pursuant to the requirements of
the Securities Exchange Act of 1934, Aerie Pharmaceuticals, Inc.
has caused this certification/notice to be signed on its behalf by
the undersigned duly authorized person.
| |
AERIE PHARMACEUTICALS, INC.
|
| |
|
|
|
Date: December 1, 2022
|
|
|
| |
By: |
/s/ Tom
Hudnall |
| |
|
Name: Tom Hudnall
|
| |
|
Title: Assistant Secretary
|
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2023 to Mar 2023
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2022 to Mar 2023
